Materials today. Bio2026ReviewDrug Delivery
Shan Q, Zheng W, Yao W, Bai Y, Ding W, Wang J, Et Al.
Alzheimer's disease (AD) is an irreversible neurodegenerative disease that has thus far suffered from unsatisfactory therapeutic outcomes. Despite ongoing research into AD pathogenesis and related drugs, few disease-modifying therapies are currently available. Moreover, efficient drug delivery is significantly…
Read the article →Clinical and experimental vaccine research2026ReviewDrug Delivery
Shahab Ms, Azizuddin S, Aslam M, Haque Mw, Ahsan Mn, Snigdha Nt, Et Al.
Biomimetic nanoparticles (BMNPs) have emerged as promising platforms for cancer vaccines and immunotherapy by combining nanoscale delivery systems with biological interfaces derived from cells or extracellular vesicles (EVs). Their therapeutic behavior is influenced by the biological source, surface composition…
Read the article →Advanced pharmaceutical bulletin2026ReviewDrug Delivery
Hari M, Subramony A, Dwivedi D, Krishnan Rs, Damodaran A, Nair Sc
Treatment for Parkinson's disease (PD) faces two significant challenges: first, the blood-brain barrier (BBB) and second, a therapeutic strategy that alleviates symptoms instead of stopping the disease progression. The BBB prevents over 98% of small-molecule drugs, leaving neuroprotective options mostly inaccessible…
Read the article →Advanced pharmaceutical bulletin2026ReviewDrug Delivery
Ainurofiq A, Rosalin Ea, Istiyono Ms, Maharani Na, Fauzy R, Sugiharti Sn, Et Al.
Chronic Obstructive Pulmonary Disease (COPD) is a condition that poses major challenges in therapeutic management, primarily due to the limitations of conventional inhalation methods in achieving optimal drug deposition and maintaining therapeutic effects over a long period. Inhalable nanomedicine has emerged as an…
Read the article →Nanomedicine (London, England)2026ReviewDrug Delivery
Malak Q, Mazumder R, Rani A, Dogra A
Retinoblastoma is an aggressive intraocular tumor in children, with a major underlying pathogenesis driven by mutations in the RB1 gene. Despite advances in management, current treatments, including systemic chemotherapy, focal therapies, radiotherapy, and enucleation, are limited by systemic toxicity, ocular…
Read the article →Journal of orthopaedic translation2026ReviewNon-viral Gene DeliveryDrug Delivery
Chen X, Sun J, Xie W, Arthur Vithran Dt, Zhang Q, Rosenholm Jm, Et Al.
Degenerative musculoskeletal diseases (DMDs) are a group of chronic conditions characterized by the progressive deterioration of tissue structure and function, primarily affecting the articular cartilage, bones, tendons, and ligaments. With global aging populations, the rising prevalence of these disorders presents a…
Read the article →Pharmaceutics2026ReviewDrug Delivery
Ban M, Zhao S, Liu Z, Zhao L
Cancer remains a major global health challenge, and nanoparticle-based drug delivery systems have emerged as a promising strategy for targeted cancer therapy. However, clinical translation is still limited by an incomplete understanding of how nanoparticles navigate the tumor microenvironment (TME) throughout the…
Read the article →Molecular therapy. Oncology2026ReviewNon-viral Gene DeliveryDrug Delivery
Bedada At, Genet S
Cancer remains a formidable global health challenge, representing the second leading cause of mortality worldwide. In 2023, there were approximately 18.5 million new cancer cases and over 10 million deaths globally, with projections estimating 30.5 million new cases and 18.6 million deaths annually by 2050. In the…
Read the article →The Journal of pharmacy and pharmacology2026ReviewDrug Delivery
Dubey S, Prakash S, Deshwal Rk, Dwivedi M
Cancer remains a major global health challenge despite significant advances in diagnosis and treatment. Conventional therapies, including chemotherapy, radiotherapy, and surgery, are frequently constrained by non-specific drug distribution, systemic toxicity, multidrug resistance (MDR), and limitations in early tumor…
Read the article →International journal of nanomedicine2026ReviewDrug Delivery
Gharatape A, Alikhanian A, Verdi J, Choonara Ye, Faridi-Majidi R
Although therapeutic opportunities beyond the scope of either field alone are offered by the combination of immune cell treatment and nanotechnology, a dominant nanoparticle design for immune-cell engineering has not been yielded by two decades of research. Here, it is contended that this lack of advancement is the…
Read the article →2023ReviewNon-viral Gene Delivery
Pinto Is, Cordeiro Ra, Faneca H
CAR T cell therapy is FDA/EMA-approved for B cell malignancies and multiple myeloma, but manufacturing relies on viral vectors—associated with safety concerns, high cost, and production challenges—or electroporation, which can be highly cytotoxic. Nanosystems may offer a safer, cost-effective alternative, but T cells…
Read the article →Acta Pharmaceutica Sinica B2022ReviewNon-viral Gene Delivery
Yingping Zeng, Sufen Li, Shufen Zhang, Li Wang, Hong Yuan, Fuqiang Hu
Cancer immunotherapy is limited by tumour heterogeneity, immune cell disability, immunosuppressive tumour microenvironment (TME), and systemic immune toxicity. Cell membrane-coated nanoparticles (CMCNs) offer a biomimetic delivery strategy that inherits source-cell functions—immune evasion, tumour targeting, and…
Read the article →Frontiers in Oncology2022ReviewNon-viral Gene Delivery
Tianqing Xin, Li Cheng, Chuchao Zhou, Yimeng Zhao, Zhenhua Hu, Xiaoyan Wu
CAR-T cell therapy has shown impressive success in haematological malignancies, but systemic toxicity (CRS, ICANS, on-target/off-tumour effects) and the complex, costly, individualized manufacturing process of autologous CAR-T cells hinder broader application. Universal allogeneic CAR-T cells have encountered safety…
Read the article →Science Advances2022ReviewNon-viral Gene Delivery
Ann E. Metzloff, Margaret M. Billingsley, Michael J. Mitchell
mRNA vaccines have entered global use, but delivering mRNA to T cells in vivo remains challenging because T cells are non-phagocytic, reside largely in lymphoid tissues, and intravenously administered lipid nanoparticles (LNPs) tend to accumulate in the liver. There is a need for precise, scalable strategies to…
Read the article →Signal Transduction and Targeted Therapy2022ReviewNon-viral Gene Delivery
Qin S, Tang X, Chen Y, Et Al.
mRNA therapeutics have fuelled hope to combat incurable diseases, but insufficient understanding of mRNA instability, immunogenicity, and delivery has impeded progress. The review argues that mRNA-based drugs—especially after the COVID-19 vaccine success—can become powerful, versatile tools, and that mRNA…
Read the article →2022ReviewDrug Delivery
Lei W, Yang C, Wu Y, Ru G, He X, Tong X, Wang S.
Conventional chemotherapy suffers from poor targeting and severe side effects, while synthetic nanocarriers are often cleared by the immune system and lack precise tumour targeting. Cell membrane-coated nanocarriers (CMCNs) offer a biomimetic strategy to improve biocompatibility, immune evasion, circulation time, and…
Read the article →2022ReviewNon-viral Gene Delivery
Chuang St, Conklin B, Stein Jb, Pan G, Lee K-B.
Immunotherapy has improved outcomes in cancer and infectious disease, but off-target effects, systemic toxicities, and variable efficacy remain limiting. Nanoscale engineering offers ways to manipulate immune cell functions—enhancing immunity against cancers and pathogens, controlling the site of immune response, and…
Read the article →Materials Today Advances2022ReviewNon-viral Gene Delivery
Randall A. Meyer, Sarah Y. Neshat, Jordan J. Green, Jose Luis Santos, And Anthony D. Tuesca
mRNA gene therapy has broad therapeutic potential (protein replacement, vaccines, regenerative medicine, oncology), but clinical translation is limited by inadequate understanding of how to target specific organs or cell types for protein expression. Reports on material properties and administration routes are…
Read the article →Advanced Healthcare Materials2022ReviewNon-viral Gene Delivery
Erin W. Kavanagh And Jordan J. Green
Viral vectors dominate gene therapy but suffer from immunogenicity, insertional mutagenesis risk, cargo-size limits, and manufacturing challenges. Non-viral nanoparticles are safer, more economical, and easier to scale, but their clinical translation has been limited by inefficient delivery, especially for DNA and…
Read the article →Heart Failure Reviews (Springer)2022ReviewNon-viral Gene Delivery
Paolo Morfino, Alberto Aimo, Vincenzo Castiglione, Carolina Galvez-Montón, Michele Emdin, Antoni Bayes-Genis
Cardiac fibrosis contributes to the pathogenesis of heart failure, myocardial infarction, and arrhythmias, but no primarily anti-fibrotic drug has been approved for cardiovascular disease. Many candidate anti-fibrotic strategies have shown promise in preclinical models yet failed to demonstrate clear clinical…
Read the article →Molecules2022ReviewNon-viral Gene Delivery
Wang H-L, Wang Z-G, Liu S-L
mRNA is a promising cancer immunotherapy platform for vaccines, cytokines, costimulatory receptors, and therapeutic antibodies, but it is unstable, immunogenic, and poorly delivered in vivo. Safer and more efficient delivery systems are needed to improve mRNA stability, cellular uptake, endosomal escape, and…
Read the article →2022ReviewNon-viral Gene Delivery
Maeki M, Uno S, Niwa A, Okada Y, Tokeshi M
RNA-loaded lipid nanoparticles (LNPs) are clinically validated for siRNA and mRNA delivery, but their therapeutic performance depends critically on reproducible control of size, size distribution, zeta potential, and RNA encapsulation efficiency. Microfluidic devices offer precise mixing, rapid ethanol dilution, high…
Read the article →Journal of Pharmaceutical Investigation.2022ReviewNon-viral Gene Delivery
Karmacharya P, Patil Br, Kim Jo
mRNA is an attractive platform for cancer immunotherapy, but its instability, susceptibility to RNase degradation, and inefficient endosomal escape limit therapeutic applications. Lipid-based nanocarriers are non-viral vectors that can protect mRNA, improve transfection, and deliver it to intracellular compartments…
Read the article →2022ReviewNon-viral Gene Delivery
Le Tmd, Yoon A-R, Thambi T, Yun C-O
Cancer immunotherapy — especially immune checkpoint inhibitors (ICIs), CAR-T cells, and oncolytic viruses (OVs) — has shown major clinical success but still faces low response rates, severe immune-related side effects, complex tumour microenvironment barriers, instability/short half-life of therapeutics, and high…
Read the article →